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with high risk features like ventricular arrhythmias and con-
gestive cardiac failure.3 Dynina et al reported that patients
with age > 85 years undergoing PCI more commonly devel-
oped stroke and renal failure requiring dialysis as compared to
patients with age < 85 years.4 In that study it was also shown
that age was not an independent risk factor for excess in
hospital mortality in the very elderly cohort.4
In the present study, both short term and long term
mortality was highest in STEMI patients as compared to
UA/NSTEMI and stable angina group. Antonsen et al showed a
similar finding with the highest short term and 1-year mor-
tality among elderly STEMI patients as compared to stable
angina patients.3
The most common type of stent used in this study in all
three groups (STEMI/NSTEMI/stable angina) was BMS as
compared to DES (67% vs. 22.6%) and only 13.3% of patients in
STEMI group had received DES. In spite of this it did not reveal
any difference in TLR rates. One of the reasons for this finding
could be inadequate power of the study to elucidate difference
in TLR between BMS and DES. This is in contrast to another
study which has shown that usage of DES in elderly patients
has increased from 0.0% to 60.3% from the year 2002e2008 and
TLR has reduced from 7.1% to 2.5% during that corresponding
period.3
Both at short term and long term follow up, the occurrence
of stent thrombosis (ST) was higher in STEMI patients. STEMI
is a known independent risk factor for ST both in young and
elderly patients. Hypercoagulable state associated with STEMI
is the possible explanation for this finding and due to per-
ceived higher risk of ST, DES is being used in only in less than
one third of elderly STEMI patients.3
Though the present study is only an observational study,
the enthusiasm for conducting randomized controlled trials
in elderly CAD patients undergoing PCI was already shattered
by premature termination of two such trials in the elderly,
Senior-PAMI and TRIANA trials, due to slow enrolment. This
study is one of the very few studies available in such a very
elderly age group and this is the only study showing long term
outcomes upto 2 years of follow up. It also gives positive hope
on bleeding risks in elderly.
In our opinion, with increasing aging of population and
increased access to healthcare, we are likely to encounter
more and more patients with CAD requiring intervention in
the very elderly cohort. We should not leave such patients at
the mercy of God and in spite of perceived increased risk, we
should try to do our best for such patients. The present study
supports this observation and shows that PCI is feasible in the
very elderly with acceptable mortality, NACE and bleeding
risks, with highest events occurring in STEMI group (like in
any other age group).r e f e r e n c e s
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2132e2140.1. Background
Catheter-based renal artery sympathetic denervation has
emerged as a novel therapy for treatment of patients with
drug-resistant hypertension. Initial studies were performed
using a single electrode radiofrequency catheter, but recent
advances in catheter design have allowed the development of
multi-electrode systems that can deliver lesions with a pre-
determined pattern. This study was designed to evaluate the
safety and efficacy of the EnligHTN, a multi-electrode system.2. Methods and results
We conducted the first-in-human, prospective, multicentre,
non-randomized study in 46 patients (67% male, mean age
60 years, and mean baseline office blood pressure 176/
96 mmHg) with drug-resistant hypertension. The primary
efficacy objective was change in office blood pressure from
baseline to 6 months. Safety measures included all adverse
events with a focus on the renal artery and other vascular
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denervation, using the EnligHTN system significantly reduced
the office blood pressure from baseline to 1, 3, and 6 months
by 28/10, 27/10 and 26/10 mmHg, respectively (P-0.0001). No
acute renal artery injury or other serious vascular complica-
tions occurred. Small, non-clinically relevant, changes in
average estimated glomerular filtration rate were reported
from baseline (87 þ 19 mL/min/1.73 m2) to 6 months post-
procedure (82 þ 20 mL/min/1.73 m2).3. Conclusion
Renal sympathetic denervation, using the EnligHTN multi-
electrode catheter results in a rapid and significant office
blood pressure reduction that was sustained through 6
months. The EnligHTN system delivers a promising therapy
for the treatment of drug-resistant hypertension.4. Perspective
Use of renal sympathectomy for control of resistant hyper-
tension dates back to the early 1930’s. However, unselective
sympathectomy was associated with significant morbidity
and was discarded with the advent of newer generations of
anti-hypertensive drugs. Interest in selective renal sym-
pathectomy again picked up in the 1980s when preclinical
research showed its value in various laboratory models of
hypertension. This culminated in the first published trial of
renal denervation therapy using single electrode catheter
system in 2005.
Subsequent trials have demonstrated the noteworthy
effects of renal denervation in resistant hypertension to be
sustained over 6 months and more. Given the relative ease of
the procedure and few procedural side effects, this therapy
may have the potential to become the next milestone in the
field of hypertension research and therapeutics.
The present trial introduces the use of a multi-electrode
renal denervation catheter with an in-human prospective
non-randomized study. This catheter has four geometrically
arranged electrodes for simultaneous ablation at different
sites. The putative advantages of a multi-electrode catheter
may be: 1) reduced manipulation of the catheter in the renal
arteries and 2) achieving more comprehensive renal dener-
vation. This may help simplify the procedure further.
In this study, 46 patients of resistant hypertension (on 3
drugs) were taken up for the procedure. Renal arteries were
selectively cannulated and the EnligHTN catheter (8 Fr com-
patible) placed proximal to the bifurcation of the renal arter-
ies. Two sets of ablations (a total of 4e8 ablations/each
ablation for 90 s) were administered. The second ablation wasadministered by pulling back the catheter by at least 1 cm and
rotating by 45. The energy generator had in-built power shut-
off in case of excess energy deliverance. The catheter and
sheath were removed sequentially and local site hemostasis
achieved. Therefore the procedure was relatively straightfor-
ward with no great deviations from normal interventional
protocols.
The trial was able to demonstrate an impressive 28/10 mm
reduction in B.P as early as the first month. Given that the
mean B.P at entry was 176/96 mm Hg, this was all the more
striking. This B.P reduction appears to have sustained till 6
months of follow-up. However, only 13% (6) patients had a
reduction in anti-hypertensive medications. Whether the
investigators plan to follow up for a longer period before
decreasing medications in the other patients remains to be
seen. Non compliance to drugs or dietary indiscretion may
have contributed to blunting of treatment effect. The SYM-
PLICITY 2 trial showed a 20% decrease in anti-hypertensive
medications. Therefore, the potency of this therapy as a
stand alone therapy remains unknown. Four patients had an
increase in anti-hypertensive medications. A larger sample
size may be able to clarify the significance of such outcomes.
Just like previous reports, this trial showed a reassuring
absence of side effects related to the procedure. In particular,
no renal artery damagewas reported (dissections, aneurysms,
flow limiting vasospasms). This is of special importance for
interventionists starting out with this procedure.
In our opinion, renal nerve denervation using the EnligHTN
multi-electrode renal denervation catheter appears to be a
relatively safe and technically simple procedure. The effect on
B.P reduction with this procedure appears to be significant,
however, large randomized controlled trials are needed to
assess efficacy with respect to cardiovascular outcomes,
applicability to larger populations and evidence of re-
innervation after this procedure. Use of this modality in less
severe hypertensive populations will possibly be the next step
in research which would ensure total freedom from all anti-
hypertensive drugs.
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